Which matters most: Number of tumors, size of the largest tumor, or total tumor volume?

Liver Transplantation

Volumn 17, Issue SUPPL. 2, 2011, Pages

  Germani, Giacomo ^a   Gurusamy, Kurinchi ^b   Garcovich, Matteo ^a   Toso, Christian ^c   Fede, Giuseppe ^a   Hemming, Alan ^d   Suh, Kyung Suk ^e   Weber, Achim ^f   Kenneth Burroughs, Andrew ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e Seoul National University   (South Korea)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 80053264025     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22336     Document Type: Article

References (78)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; for SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
2. Marelli L, Grasso A, Pleguezuelo M, Martines H, Stigliano R, Dhillon AP, et al. Tumour size and differentiation in predicting recurrence of hepatocellular carcinoma after liver transplantation: external validation of a new prognostic score. Ann Surg Oncol 2008; 15: 3503-3511.
3. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al.; for Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
4. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR,. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
5. Parmar MK, Torri V, Stewart L,. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834. (Pubitemid 28562978)
6. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558. (Pubitemid 34746062)
7. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699. (Pubitemid 26079803)
8. Altman DG, Bland JM,. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219. (Pubitemid 36143396)
9. Regalia E, Coppa J, Pulvirenti A, Romito R, Schiavo M, Burgoa L, Mazzaferro V,. Liver transplantation for small hepatocellular carcinoma in cirrhosis: analysis of our experience. Transplant Proc 2001; 33: 1442-1444. (Pubitemid 32237918)
10. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP,. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765-774. (Pubitemid 35012284)
11. Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301-1311. (Pubitemid 39406087)
12. Ravaioli M, Ercolani G, Cescon M, Vetrone G, Voci C, Grigioni WF, et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 2004; 10: 1195-1202. (Pubitemid 39248420)
13. Löhe F, Angele MK, Gerbes AL, Löhrs U, Jauch KW, Schauer RJ,. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2005; 31: 994-999. (Pubitemid 41671113)
14. Merli M, Nicolini G, Gentili F, Novelli G, Iappelli M, Casciaro G, et al. Predictive factors of outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Transplant Proc 2005; 37: 2535-2540. (Pubitemid 41354662)
15. Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 2708-2716.
16. Grasso A, Stigliano R, Morisco F, Martines H, Quaglia A, Dhillon AP, et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation 2006; 81: 1532-1541. (Pubitemid 43890890)
17. Morioka D, Tanaka K, Matsuo K, Takeda K, Ueda M, Sugita M, et al. Applicability of the Milan criteria for determining liver transplantation as a first-line treatment for hepatocellular carcinoma. Ann Surg Oncol 2006; 13: 1500-1510. (Pubitemid 44749662)
18. Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267. (Pubitemid 44194595)
19. Oya H, Sato Y, Yamamoto S, Nakatsuka H, Kobayashi T, Hara Y, et al. Comparison between human-telomerase reverse transcriptase mRNA and alpha-fetoprotein mRNA as a predictive value for recurrence of hepatocellular carcinoma in living donor liver transplantation. Transplant Proc 2006; 38: 3636-3639. (Pubitemid 44908547)
20. Söderdahl G, Bäckman L, Isoniemi H, Cahlin C, Höckerstedt K, Broomé U, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006; 19: 288-294.
21. Takada Y, Ueda M, Ito T, Sakamoto S, Haga H, Maetani Y, et al. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 2006; 12: 912-919. (Pubitemid 43960366)
22. Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006; 45: 246-253.
23. Yokoi H, Isaji S, Yamagiwa K, Tabata M, Nemoto A, Sakurai H, et al. The role of living-donor liver transplantation in surgical treatment for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006; 13: 123-130.
24. Chao SD, Roberts JP, Farr M, Yao FY,. Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma. Am J Transplant 2007; 7: 1594-1600. (Pubitemid 46776249)
25. Chen J, Xu X, Ling Q, Wu J, Zheng SS,. Role of Pittsburgh modified TNM criteria in prognosis prediction of liver transplantation for hepatocellular carcinoma. Chin Med J (Engl) 2007; 120: 2200-2203.
26. Cillo U, Vitale A, Grigoletto F, Gringeri E, D'Amico F, Valmasoni M, et al. Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transplant 2007; 7: 972-981. (Pubitemid 46481197)
27. Obed A, Beham A, Püllmann K, Becker H, Schlitt HJ, Lorf T,. Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. World J Gastroenterol 2007; 13: 761-767.
28. Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Aishima S, Terashi T, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007; 83: 893-899. (Pubitemid 46682729)
29. Sotiropoulos GC, Lang H, Nadalin S, Neuhäuser M, Molmenti EP, Baba HA, et al. Liver transplantation for hepatocellular carcinoma: University Hospital Essen experience and metaanalysis of prognostic factors. J Am Coll Surg 2007; 205: 661-675. (Pubitemid 47615488)
30. Suh KS, Cho EH, Lee HW, Shin WY, Yi NJ, Lee KU,. Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis 2007; 25: 329-333. (Pubitemid 350014961)
31. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 2007; 141: 598-609. (Pubitemid 46616932)
32. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Wright F, et al. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int 2007; 20: 747-753. (Pubitemid 47221058)
33. Herrero JI, Sangro B, Pardo F, Quiroga J, Iñarrairaegui M, Rotellar F, et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 2008; 14: 272-278. (Pubitemid 351425478)
34. Kim BW, Park YK, Kim YB, Wang HJ, Kim MW,. Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: feasibility of the Milan criteria and operative risk. Transplant Proc 2008; 40: 3558-3561.
35. Silva M, Moya A, Berenguer M, Sanjuan F, Lõpez-Andujar R, Pareja E, et al. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 2008; 14: 1449-1460.
36. Sotiropoulos GC, Beckebaum S, Lang H, Frilling A, Molmenti EP, Cicinnati VR, et al. Single-center experience on liver transplantation for hepatocellular carcinoma arising in alcoholic cirrhosis: results and ethical issues. Eur Surg Res 2008; 40: 7-13. (Pubitemid 350085264)
37. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-862.
38. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85: 1726-1732.
39. Chen JW, Kow L, Verran DJ, McCall JL, Munn S, Balderson GA, et al. Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF criteria. An analysis of liver transplantation in HCC in Australia and New Zealand. HPB (Oxford) 2009; 11: 81-89.
40. D'Amico F, Schwartz M, Vitale A, Tabrizian P, Roayaie S, Thung S, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009; 15: 1278-1287.
41. Fan J, Yang GS, Fu ZR, Peng ZH, Xia Q, Peng CH, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol 2009; 135: 1403-1412.
42. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl 2009; 15: 859-868.
43. Qasim A, Zaman MB, Maguire D, Geoghegan J, Gibney R, Nolan N, et al. Hepatic transplantation outcomes for carefully selected cirrhotic patients with hepatocellular carcinoma: experience at a small- to medium-volume centre. Ir J Med Sci 2009; 178: 469-472.
44. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009; 87: 531-537.
45. Kornberg A, Küpper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, Wilberg J,. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol 2010; 36: 275-280.
46. Lee KK, Kim DG, Moon IS, Lee MD, Park JH,. Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol 2010; 101: 47-53.
47. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-509. (Pubitemid 47312148)
48. Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007; 13: 543-551. (Pubitemid 46605857)
49. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP,. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7: 2587-2596. (Pubitemid 47561609)
50. Halazun KJ, Hardy MA, Rana AA, Woodland DC IV, Luyten EJ, Mahadev S, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250: 141-151.
51. Lai Q, Merli M, Ginanni Corradini S, Mennini G, Gentili F, Molinaro A, et al. Predictive factors of recurrence of hepatocellular carcinoma after liver transplantation: a multivariate analysis. Transplant Proc 2009; 41: 1306-1309.
52. Saab S, Yeganeh M, Nguyen K, Durazo F, Han S, Yersiz H, et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009; 15: 1525-1534.
53. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, Meyer C, Gugenheim J, Durand F, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006; 12: 1761-1769. (Pubitemid 44911801)
54. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM,. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-838.
55. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403. (Pubitemid 32496976)
56. Li J, Yan LN, Yang J, Chen ZY, Li B, Zeng Y, et al. Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients. World J Gastroenterol 2009; 15: 4170-4176.
57. Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, et al. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010; 31: 415-423.
58. Chan EY, Larson AM, Fix OK, Yeh MM, Levy AE, Bakthavatsalam R, et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl 2008; 14: 956-965. (Pubitemid 352003894)
59. Salizzoni M, Romagnoli R, Lupo F, David E, Mirabella S, Cerutti E, Ottobrelli A,. Microscopic vascular invasion detected by anti-CD34 immunohistochemistry as a predictor of recurrence of hepatocellular carcinoma after liver transplantation. Transplantation 2003; 76: 844-848. (Pubitemid 37140230)
60. Figueras J, Jaurrieta E, Valls C, Benasco C, Rafecas A, Xiol X, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997; 25: 1485-1489. (Pubitemid 27250773)
61. Klintmalm GB,. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998; 228: 479-490. (Pubitemid 30194392)
62. Figueras J, Jaurrieta E, Valls C, Ramos E, Serrano T, Rafecas A, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 2000; 190: 580-587. (Pubitemid 30230706)
63. Iwatsuki S, Dvorchik I, Marsh JW, Madariaga JR, Carr B, Fung JJ, Starzl TE,. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 2000; 191: 389-394.
64. Figueras J, Ibañez L, Ramos E, Jaurrieta E, Ortiz-de-Urbina J, Pardo F, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl 2001; 7: 877-883. (Pubitemid 33040462)
65. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ,. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233: 652-659. (Pubitemid 32378649)
66. Tamura S, Kato T, Berho M, Misiakos EP, O'Brien C, Reddy KR, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001; 136: 25-30.
67. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-540. (Pubitemid 38443593)
68. Todo S, Furukawa H,; for Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004; 240: 451-459.
69. Pérez de Luque D, Lõpez Vallejos P, Montero Alvarez JL, Fraga Rivas E, Barrera Baena P, Costán Rodero G, et al. Survival of patients receiving a liver transplant for hepatocellular carcinoma, and risk of tumor recurrence. Rev Esp Enferm Dig 2006; 98: 899-906. (Pubitemid 350269480)
70. Kondili LA, Lala A, Gunson B, Hubscher S, Olliff S, Elias E, et al. Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. Eur J Surg Oncol 2007; 33: 868-873. (Pubitemid 47279043)
71. Li N, Zhou J, Weng D, Zhang C, Li L, Wang B, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007; 13: 5847-5854. (Pubitemid 47583910)
72. Löhe F, Angele MK, Rentsch M, Graeb C, Gerbes A, Löhrs U, et al. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant 2007; 21: 696-701. (Pubitemid 350056135)
73. Wu L, Xu X, Shen J, Xie H, Yu S, Liang T, et al. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol 2007; 96: 62-68. (Pubitemid 47015450)
74. Barakat O, Wood RP, Ozaki CF, Ankoma-Sey V, Galati J, Skolkin M, et al. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl 2010; 16: 289-299.
75. Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14: 1107-1115.
76. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A,. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145-151. (Pubitemid 23229140)
77. Volk ML, Vijan S, Marrero JA,. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008; 8: 839-846. (Pubitemid 351347750)
78. Freeman RB, Mithoefer A, Ruthazer R, Nguyen K, Schore A, Harper A, Edwards E,. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl 2006; 12: 1504-1511. (Pubitemid 44594281)